Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Chan-Mi Lee, Margaret Wang, Aarthi Rajkumar, Cassandra Calabrese, Leonard Calabrese
BACKGROUND/PURPOSE: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known regarding its nosology, clinical manifestations, or response to treatment and outcomes. METHODS: To address these gaps, we used the Preferred Reporting Items for Systemic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) framework to further define this complication. Two independent PUBMED searches in September and November of 2022 revealed 127 publications with 37 excluded from title by relevance, 43 excluded by article type, and 23 excluded due to lack of biopsy results, or biopsy negative for vasculitis...
March 27, 2024: Seminars in Arthritis and Rheumatism
#22
JOURNAL ARTICLE
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D d'Arienzo, Florentia Mina, Juliane A Czapla, Aleigha R Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B Johnson, Serigne N Lo, Georgina V Long, Alexander M Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M Boland, Ryan J Sullivan, Andrew J S Furness, Ruth Plummer, Keith T Flaherty
No abstract text is available yet for this article.
May 2024: EClinicalMedicine
#23
Tanja Fetter, Simon Fietz, Maya Bertlich, Christine Braegelmann, Luka de Vos-Hillebrand, Joerg Wenzel, Annkristin Heine, Jennifer Landsberg, Philipp Jansen
INTRODUCTION: Over the past decade, immune checkpoint inhibitors such as antibodies against cytotoxicity T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have become an important armamentarium against a broad spectrum of malignancies. However, these specific inhibitors can cause adverse autoimmune reactions by impairing self-tolerance. Hematologic side effects of immune checkpoint inhibitors, including autoimmune hemolytic anemia (AIHA), are rare but can be life-threatening...
2024: Frontiers in Immunology
#24
JOURNAL ARTICLE
Paul Gougis, Floriane Jochum, Baptiste Abbar, Elise Dumas, Kevin Bihan, Bénédicte Lebrun-Vignes, Javid Moslehi, Jean-Philippe Spano, Enora Laas, Judicael Hotton, Fabien Reyal, Anne-Sophie Hamy, Joe-Elie Salem
BACKGROUND: Immune-checkpoint inhibitors (ICI) have revolutionized cancer treatment by harnessing the immune system but ICI can induce life-threatening immune-related adverse events (irAE) affecting every organ. METHODS: We extracted irAE from VigiBase, the international pharmacovigilance database, first reported in 2008 until 01/2023 to characterize irAE reporting trends, clinical features, risk factors and outcomes. FINDINGS: We distinguished 25 types of irAE (n = 50,347cases, single irAE/case in 84...
April 2024: EClinicalMedicine
#25
JOURNAL ARTICLE
Bixia Tang, Rong Duan, Xiaoshi Zhang, Shuikui Qin, Di Wu, Jing Chen, Hong Yao, Zhihong Chi, Jun Guo, Xieqiao Yan
BACKGROUND: To investigate the efficacy and toxicity after long-term follow-up of anti-PD-1 antibody in advanced melanoma with predominantly acral and mucosal subtypes. METHODS AND PATIENTS: In the POLARIS-01 phase II trial, 128 Chinese patients with advanced melanoma refractory to standard therapy received toripalimab until disease progression or unacceptable toxicity for ≤2 years. For those who progressed after discontinuation due to 2-year treatment completion, rechallenge was allowed...
March 28, 2024: Oncologist
#26
JOURNAL ARTICLE
Na-Ra Han, Hi-Joon Park, Seong-Gyu Ko, Phil-Dong Moon
Cancer immunotherapy as a promising anti-cancer strategy has been widely studied in recent years. Stigmasterol (STIG), a phytosterol, is known to have various pharmacological effects, including anti-inflammatory effects. However, the pharmacological role of STIG on melanoma immunotherapy has not been investigated. The present study demonstrates the anti-melanoma potency of STIG through the regulation of PD-L1 levels. The results reveal that STIG reduces reactive oxygen species (ROS) levels induced by hydrogen peroxide and increases glutathione levels decreased by α-MSH in B16F10 cells...
March 21, 2024: Antioxidants (Basel, Switzerland)
#27
REVIEW
Ana Dillen, Indy Bui, Megan Jung, Stephanie Agioti, Apostolos Zaravinos, Benjamin Bonavida
During the last decade, we have witnessed several milestones in the treatment of various resistant cancers including immunotherapeutic strategies that have proven to be superior to conventional treatment options, such as chemotherapy and radiation. This approach utilizes the host's immune response, which is triggered by cancer cells expressing tumor-associated antigens or neoantigens. The responsive immune cytotoxic CD8+ T cells specifically target and kill tumor cells, leading to tumor regression and prolongation of survival in some cancers; however, some cancers may exhibit resistance due to the inactivation of anti-tumor CD8+ T cells...
March 21, 2024: Cancers
#28
JOURNAL ARTICLE
Magdalena Absmaier-Kijak, Caterina Iuliano, Susanne Kaesler, Tilo Biedermann, Christian Posch, Knut Brockow
Immune checkpoint inhibition (ICI) improves outcomes in melanoma patients, but associated T-cell activation frequently leads to immune-related cutaneous adverse events (cutAEs). To dynamically identify T-cell subtypes and immune signatures associated with cutAEs, a pilot study was performed in stage III-IV melanoma patients using blood samples for flow cytometry and cytokine analysis. Blood samples were taken from patients before initiation of ICI (naive), at the onset of a cutAE, and after 6 months of ICI treatment...
March 20, 2024: Cancers
#29
JOURNAL ARTICLE
Alexandru Dorin Adrian Silași, Anna Carolin Sievert, Paul Danciu, Andrei Vlad Lefter, Vlad Adrian Afrasanie, Daniel Sur
BACKGROUND: This retrospective study evaluates patients with stage IV melanoma treated with nivolumab and ipilimumab combination therapy from two regional oncology centers in Romania from the year 2019 to the end of 2022. METHODS: The data were analyzed in SAS for Windows, V9.4. LDH means were stratified by the number of metastatic sites before treatment and compared using an independent sample T-test. The survival curves were estimated using the Kaplan-Meier method, and the survival distributions were compared with the log-rank test...
March 20, 2024: Diagnostics
#30
JOURNAL ARTICLE
Myung Soo Chang, Seung Won Lee, Sunyeup Kim, Christopher Seungkyu Lee, Suk Ho Byeon, Sung Soo Kim, Yong Joon Kim
Our findings suggest that, while incident uveitis is rare in patients with cancer treated with anti-PD-1/PD-L1 inhibitors, there is an increased risk in those with skin melanoma, warranting vigilant monitoring for uveitis in this subgroup.
March 22, 2024: Ophthalmology
#31
JOURNAL ARTICLE
Bozhi Shen, Jie Mei, Rui Xu, Yun Cai, Mengyun Wan, Ji Zhou, Junli Ding, Yichao Zhu
Melanoma is the most suitable tumor type for immunotherapy, but not all melanoma patients could respond to immunotherapy. B7 homolog 3 (B7-H3) belongs to the B7 family and is overexpressed in a number of malignant tumors, but the expression pattern of B7-H3 in melanoma has not been well summarized. The expression of B7-H3 was investigated in melanoma and its correlations with features of the tumor microenvironment (TME) by using various public databases, including the Cancer Genome Atlas (TCGA), the GEPIA, and the Human Protein Atlas databases...
March 18, 2024: Pathology, Research and Practice
#32
JOURNAL ARTICLE
Rikke B Holmstroem, Sidsel Pedersen, Rebecca Jurlander, Kasper Madsen, Marco Donia, Christina H Ruhlmann, Henrik Schmidt, Charlotte A Haslund, Lars Bastholt, Inge Marie Svane, Eva Ellebaek
BACKGROUND: Clinical trials have demonstrated promising outcomes for adjuvant immunotherapy in patients with resected melanoma. Real-life data provide valuable insights to support patient guidance and treatment decisions. METHODS: Observational population-based study examining a national cohort of patients with resected stage III-IV melanoma referred for adjuvant therapy. Data were extracted from the Danish Metastatic Melanoma Database (DAMMED). RESULTS: Between November 2018 and January 2022, 785 patients received adjuvant anti-PD-1...
March 19, 2024: European Journal of Cancer
#33
JOURNAL ARTICLE
Wei Sun, Yu Zhu, Zijian Zou, Lu Wang, Jingqin Zhong, Kangjie Shen, Xinyi Lin, Zixu Gao, Wanlin Liu, Yinlam Li, Yu Xu, Ming Ren, Tu Hu, Chuanyuan Wei, Jianying Gu, Yong Chen
Rationale: Immune checkpoint inhibitors targeting the programmed cell death (PD)-1/PD-L1 pathway have promise in patients with advanced melanoma. However, drug resistance usually results in limited patient benefits. Recent single-cell RNA sequencing studies have elucidated that MM patients display distinctive transcriptional features of tumor cells, immune cells and interstitial cells, including loss of antigen presentation function of tumor cells, exhaustion of CD8+T and extracellular matrix secreted by fibroblasts to prevents immune infiltration, which leads to a poor response to immune checkpoint inhibitors (ICIs)...
2024: Theranostics
#34
JOURNAL ARTICLE
Xue Bai, Aleigha R Lawless, Juliane A Czapla, Stefanie C Gerstberger, Benjamin C Park, Seungyeon Jung, Rebecca Johnson, Naoya Yamazaki, Dai Ogata, Yoshiyasu Umeda, Caili Li, Jun Guo, Keith T Flaherty, Yasuhiro Nakamura, Kenjiro Namikawa, Georgina V Long, Alexander M Menzies, Douglas B Johnson, Ryan J Sullivan, Genevieve M Boland, Lu Si
BACKGROUND: Anti-Program-Death-1 (PD-1) is a standard adjuvant therapy for patients with resected melanoma. We hypothesized that there are discrepancies in survival, recurrence pattern and toxicity to adjuvant PD-1 between different ethnicities and melanoma subtypes. OBJECTIVE: We performed a multicenter cohort study incorporating 6 independent institutions in Australia, China, Japan, and the United States. The primary outcomes were recurrence free survival (RFS) and overall survival (OS)...
June 2024: JAAD international
#35
REVIEW
Jinyu Wang, Zehua Li, Hongbo Yin
INTRODUCTION: Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the eye and the liver, the most frequent site of metastasis. Nevertheless, the therapeutic outcomes reported currently are less pessimistic. METHODS: In this review, we provide an overview of recent studies of immune checkpoint inhibitors in uveal melanoma and its metastasis and classify studies in this field into three groups: monotherapy of immune checkpoint inhibitors, dual-agent immune checkpoint inhibitors, and immune checkpoint inhibitors combined with other systemic or regional therapies...
March 18, 2024: Ophthalmology and Therapy
#36
Zachary Buchwald, Yang Shen, Erin Connolly, Meili Aiello, Chengjing Zhou, Prasanthi Chappa, Haorui Song, Patan Tippitak, Tarralyn Clark, Maria Cardenas, Nataliya Prokhnevska, Annapaola Mariniello, Meghana Pagadala, Vishal Dhere, Sarwish Rafiq, Aparna Kesarwala, Alexandre Orthwein, Susan Thomas, Mohammad Khan, J Brandon Dixon, Gregory B Lesinski, Michael Lowe, Haydn Kissick, David Yu, Chrystal Paulos, Nicole Schmitt
Radiotherapy (RT) and anti-PD-L1 synergize to enhance local and distant (abscopal) tumor control. However, clinical results in humans have been variable. With the goal of improving clinical outcomes, we investigated the underlying synergistic mechanism focusing on a CD8+ PD-1+ Tcf-1+ stem-like T cell subset in the tumor-draining lymph node (TdLN). Using murine melanoma models, we found that RT + anti-PD-L1 induces a novel differentiation program in the TdLN stem-like population which leads to their expansion and differentiation into effector cells within the tumor...
March 6, 2024: Research Square
#37
JOURNAL ARTICLE
Martina Morelli, Maria Luigia Carbone, Giovanni Luca Scaglione, Claudia Scarponi, Valentina Di Francesco, Sabatino Pallotta, Federica De Galitiis, Siavash Rahimi, Stefania Madonna, Cristina Maria Failla, Cristina Albanesi
INTRODUCTION: Immunotherapy with biologics targeting programmed cell death protein-1 (PD-1) is highly effective in the treatment of various malignancies. Nevertheless, it is frequently responsible for unexpected cutaneous manifestations, including psoriasis-like dermatitis. The pathogenesis of anti-PD-1-induced psoriasis has yet to be clarified, even though it is plausible that some innate and adaptive immunity processes are in common with canonical psoriasis. The genetic predisposition to psoriasis of patients could also be a contributing factor...
2024: Frontiers in Immunology
#38
JOURNAL ARTICLE
Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C Hassel, Michael Erdmann, Andrea Forschner, Douglas B Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Schulz, Carola Berking, Christoph Pöttgen, Alexander M Menzies, Georgina V Long, Reinhard Dummer, Elisabeth Livingstone, Dirk Schadendorf, Lisa Zimmer
BACKGROUND: Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI with TT; however, clinical trials evaluating the efficacy of triplet combinations in first-line setting showed limited advantage compared to TT only. METHODS: We conducted a retrospective, multicenter study, that included patients with advanced melanoma who were treated with BRAF/MEK inhibitors in combination with an anti-PD-(L)1 antibody (triplet therapy) after failure of at least one anti-PD-(L)1-based therapy and one TT in seven major melanoma centers between February 2016 and July 2022...
March 1, 2024: European Journal of Cancer
#39
JOURNAL ARTICLE
Qi Wan, Yuhua Deng, Ran Wei, Ke Ma, Jing Tang, Ying-Ping Deng
Along with the increasing knowledge of long noncoding RNA, the interaction between the long noncoding RNA (lncRNA) and tumor immune infiltration is increasingly valued. However, there is a lack of understanding of correlation between regulation of specific lncRNAs and tumor-infiltrating macrophages within melanoma. In this research, a macrophage associated lncRNA signature was identified by multiple machine learning algorithms and the robust and effectiveness of signature also validated in other independent datasets...
March 13, 2024: Aging
#40
JOURNAL ARTICLE
Agata Marjańska, Katarzyna Pawińska-Wąsikowska, Aleksandra Wieczorek, Monika Drogosiewicz, Bożenna Dembowska-Bagińska, Katarzyna Bobeff, Wojciech Młynarski, Katarzyna Adamczewska-Wawrzynowicz, Jacek Wachowiak, Małgorzata A Krawczyk, Ninela Irga-Jaworska, Jadwiga Węcławek-Tompol, Krzysztof Kałwak, Małgorzata Sawicka-Żukowska, Maryna Krawczuk-Rybak, Anna Raciborska, Agnieszka Mizia-Malarz, Agata Sobocińska-Mirska, Paweł Łaguna, Walentyna Balwierz, Jan Styczyński
BACKGROUND/AIM: The role of immune checkpoint inhibitors (ICIs; anti-PD1) in the treatment of childhood cancers is still evolving. The aim of this nationwide retrospective study was to assess the safety and effectiveness of ICIs used in a group of 42 patients, with a median age of 13.6 years, with various types of advanced malignancies treated in pediatric oncology centers in Poland between 2015 and 2023. RESULTS: The indications for treatment with anti-PD1 were as follows: Hodgkin lymphoma (11); malignant skin melanoma (9); neuroblastoma (8); and other malignancies (14)...
February 28, 2024: Cancers
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
